DOCSLIB.ORG

Conventional and Atypical Opioids

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Conventional and atypical opioids Not all opioids are the same The atypical opioids: buprenorphine, tramadol and tapentadol Use of opioids in chronic noncancer pain Acute and chronic musculoskeletal pain – pharmacological management Tapering off opioid analgesia Opioid prescribing in general practice: a proposed approach Formerly MODERN MEDICINE This supplement is provided as an educational service by SEQIRUS PTY LTD © MEDI-MATION/SPL Copyright 2018 Medicine Today Pty Ltd Permission granted by Medicine Today for Pain Australia to circulate this supplement © Medicine Today 2018 MEDICINE TODAY GROUP WEBSITES Have you registered for MedicineToday digital access? ENHANCE the value of the print edition with digital access toMedicine Today content. CardiologyINCORPORATING OCTOBER 2018 VOL 19 NUMBER 10 MONTH 2000 VOL 0 NUMBER Today VOLUME 19 NUMBER 10 OCTOBER 2018 Medicine Today SHORT-ACTING CONTRACEPTION METHODS Contraception An update on short-acting methods ❙ REGISTER at medicinetoday.com.au EYE STRAIN ❙ for full access to the current and previous issues ALLERGIC RHINOCONJUNCTIVITIS plus CPD modules and fi nd: ❙ • more than 1500 peer-reviewed clinical articles PRIAPISM ❙ • more than 100 patient handouts ready to print CHRONIC NAUSEA, AND MORE Feature Articles EARN 6 CPD POINTS Regular Series • more than 200 clinical fl owcharts Eye strain: focus on causes Priapism related to antipsychotic and treatment drug use • the full dermatology quiz archive Allergen-specifi c immunotherapy Interpersonal psychotherapy for allergic rhinoconjunctivitis Dermatology case: a girl with a • reader-friendly presentations severe blistering rash Investigation and management of • clinical case studies on diagnosis and management 100007893 chronic nausea Formerly MODERN MEDICINE (1957–1999) • news briefi ngs from scientifi c journals Cover_MT Oct.indd 2 2/10/2018 3:07 PM • supplements including Dermatology Collections MARCH 2018 VOL 5 NO 1 A MEDICINE TODAY PUBLICATION JULY 2017 VOL 7 NO 1 A MEDICINE TODAY PUBLICATION MAY 2018 VOL 7 NO 2 A MEDICINE TODAY PUBLICATION A MEDICINE TODAY PUBLICATION OCTOBER 2018 VOL 3 NO 2 Respiratory Medicineedicine PPEER REVIEWEDain UPDATES ManagementFOR MEDICAL PRACTITIONERS Today PEER REVIEWED UPDATES FOR MEDICAL PRACTITIONERS Today Today EnPEER REVIEWEDdo UPDATES FORcri MEDICAL PRACTITIONERSnologygy CardPEER REVIEWED UPDATES FOR MEDICALiol PRACTITIONERSogygy Today FEATURES FEATURE FEATURES Managing pain in rheumatoid arthritis Complexities in managing Abdominal aortic obesity in COPD Pain in cancer survivors aneurysms: surgery FEATURES PERSPECTIVES and surveillance Graves’ disease: Ovulation induction: PERSPECTIVES PERSPECTIVES Inhaled corticosteroids in Intensive lipid-modifying overcoming the challenges when and how to use it Clinical use of placebo in pain COPD: when to use therapy Initiating insulin in Managing statin management ECG EDUCATION primary care intolerance in diabetes It’s that time of year PERSPECTIVES What is the place of interventional again: seasonal allergic rhinitis Alcoholic cardiomyopathy Misinterpretation of ACUTE PRESENTATIONS pain procedures? Hyponatraemia in A guide to quitting smoking GP EMERGENCY MANAGEMENT diagnostic test results an elderly woman CASE STUDY in mental illness Faint of heart: syncope Emerging therapies A man with recurrent chronic Stigma and lung disease – and familial long QT syndrome for heart failure Adrenal headaches using codeine what we can do Nutrition and diet incidentalomas Shoulder pain Severe asthma What to suggest after MI Key issues in screening and diagnosis How to assess, when to refer Reducing the burden Cover_CT July.indd 401 21/06/2017 5:13 PM Cover_ET May-ML.indd 400 20/04/2018 4:06 PM Cover_RMT Oct.indd 400 25/09/2018 11:32 AM Cover_PMT Mar-ML.indd 400 27/02/2018 3:47 PM cardiologytoday.com.au endocrinologytoday.com.au painmanagementtoday.com.au respiratorymedicinetoday.com.au Use your MedicineToday login to access all fi ve sites Sign up for email alerts and never miss an issue! medicinetoday.com.au THE PEER REVIEWED JOURNAL OF CLINICAL PRACTICE MT Digital_Ad_NEW.inddPermission 1 granted by Medicine Today for Pain Australia to circulate this supplement © Medicine Today 2018 25/10/2018 10:11 AM SUPPLEMENT CONVENTIONAL AND ATYPICAL OPIOIDS SEPTEMBER 2018 THE PEER REVIEWED JOURNAL OF CLINICAL PRACTICE ISSN 1443-430X MANAGING EDITOR Jacqueline George BSc(Hons) SENIOR ASSISTANT EDITOR FOREWORD FROM THE SUPPLEMENT EDITOR Kerrie Lawson PhD, ELS ASSISTANT EDITORS ver the past 30 years, opioids have been on a rollercoaster ride. This ride began with the Christine Binskin BSc Aleta van Kerkhoff MSc, GDipClinEpid, ELS ‘opiophobia’ of the ‘80s, which was then successfully overcome, at least in developed Marie Lofthouse BSc(Hons) Ocountries, by the UK’s hospice movement and the WHO through its step-ladder approach CONSULTANT MEDICAL EDITORS to cancer pain. Subsequently, the success of opioids in the management of cancer pain was Chris Pokorny FRACP inappropriately translated to all chronic noncancer pain, ignoring the complexity of the John Dearin FRACGP, DipGer, DipRehabMed, MBioEth sociopsychobiomedical origin of most of these pain states. PRODUCTION/DESIGN MANAGER The new approach did not help most sufferers of chronic pain to achieve their goals of improved quality of life and Maria Marmora reduced disability, but resulted in increased risks of opioid abuse and even fatal overdose. Shocking mortality GROUP SALES & MARKETING MANAGER statistics and headlines such as ‘A flood of opioids, a tide of rising deaths’ (in The New England Journal of Medicine) Prue Anderson SALES & MARKETING C0-ORDINATOR led to the recognition of the ‘opioid epidemic’ as a major healthcare issue. Therese Dahlström It is therefore necessary to stress the relevance of a multimodal and interdisciplinary approach to the management ACCOUNTS Pauline Burnard of chronic pain with an emphasis on active treatment strategies leading to self-efficacy and self-management. SUBSCRIPTIONS CO-ORDINATOR Medications can sometimes help to achieve these goals, but with regard to opioids this should be preferably with Katrina Lehmann use of atypical opioids. The atypical opioids, transdermal buprenorphine, tramadol and tapentadol, have different PUBLISHER/EDITORIAL DIRECTOR mechanisms of action than conventional opioids that rely exclusively on mu-receptor Judy Passlow agonism. This explains their different effects and adverse effects, as well as their PUBLISHER/MANAGING DIRECTOR lower risk of abuse and toxicity. Tony Scott SYDNEY OFFICE This supplement addresses concepts of chronic pain management and important 2/36 Bydown Street, principles of the use of opioids in this setting. Neutral Bay NSW 2089 POSTAL ADDRESS Professor Stephan Schug is Professor and Chair of Anaesthesiology PO Box 1473, Neutral Bay and Pain Medicine at the University of Western Australia; NSW 2089 and Director of Pain Medicine at Royal Perth Hospital, Perth, WA. TELEPHONE (02) 9908 8577 PAGE 5 FACSIMILE (02) 9908 7488 FEATURE ARTICLES PEER REVIEWED Printed by Blue Star Web, Sydney. Copyright 2018 Medicine Today Pty Ltd. No part of this publication may be reproduced, stored in a retrieval system, Not all opioids are the same 2 or transmitted in any form or by any means (electronic, mechanical or photocopy STEPHAN A. SCHUG recording or otherwise) in whole or in part, in any form whatsoever without the prior written permission of the Publisher. The atypical opioids: buprenorphine, tramadol The articles in this supplement and tapentadol 5 have been specially STEPHAN A. SCHUG PAGE 12 commissioned for this publication or were originally published in a Medicine Today Use of opioids in chronic noncancer pain 12 publication and updated. STEPHAN A. SCHUG, MIR WAIS SEKANDARZAD Each has been subjected to Medicine Today’s usual rigorous peer review process. Acute and chronic musculoskeletal pain – pharmacological This supplement has been management 16 sponsored by an unrestricted STEPHAN A. SCHUG, AHMAD AFIFI MOHD ARSHAD educational grant from Seqirus Pty Ltd. The opinions expressed in the articles are Tapering off opioid analgesia 23 PAGE 16 those of the authors and not APO DEMIRKOL necessarily those of Seqirus. Some products and/ or indications mentioned may not Opioid prescribing in general practice: a proposed be approved for use in approach 26 Australia. Please review Product Information, available MILTON L. COHEN, ALEX D. WODAK from the manufacturer, before prescribing any agent PAGE 26 mentioned in these articles. MedicineToday ❙ Conventional and Atypical Opioids Supplement SEPTEMBER 2018 1 Permission granted by Medicine Today for Pain Australia to circulate this supplement © Medicine Today 2018 EDITORIAL Not all opioids are the same STEPHAN A. SCHUG MD, FANZCA, FFPMANZCA, EDPM Opioids are the most effective analgesics available but when used inappropriately can cause problems to individual patients and society as a whole. Recognising the differences between conventional and atypical opioids can help prevent some of these adverse consequences. pioids have been used by as nausea, vomiting, constipation, urinary humans for many thousands retention, sedation, confusion or agitation of years.1 Initially, these were have been well described.1,2 extracts of the poppy seed, Owhich were then chemically defined in Overcoming the fear of the form of morphine and subsequently opioid use modified by the pharmaceutical industry Initially opioids were freely available in to the wide range of medicines available many countries, but increasing concerns to us
Recommended publications
  • Biased Versus Partial Agonism in the Search for Safer Opioid Analgesics

    Biased Versus Partial Agonism in the Search for Safer Opioid Analgesics

    molecules Review Biased versus Partial Agonism in the Search for Safer Opioid Analgesics Joaquim Azevedo Neto 1 , Anna Costanzini 2 , Roberto De Giorgio 2 , David G. Lambert 3 , Chiara Ruzza 1,4,* and Girolamo Calò 1 1 Department of Biomedical and Specialty Surgical Sciences, Section of Pharmacology, University of Ferrara, 44121 Ferrara, Italy; [email protected] (J.A.N.); [email protected] (G.C.) 2 Department of Morphology, Surgery, Experimental Medicine, University of Ferrara, 44121 Ferrara, Italy; [email protected] (A.C.); [email protected] (R.D.G.) 3 Department of Cardiovascular Sciences, Anesthesia, Critical Care and Pain Management, University of Leicester, Leicester LE1 7RH, UK; [email protected] 4 Technopole of Ferrara, LTTA Laboratory for Advanced Therapies, 44122 Ferrara, Italy * Correspondence: [email protected] Academic Editor: Helmut Schmidhammer Received: 23 July 2020; Accepted: 23 August 2020; Published: 25 August 2020 Abstract: Opioids such as morphine—acting at the mu opioid receptor—are the mainstay for treatment of moderate to severe pain and have good efficacy in these indications. However, these drugs produce a plethora of unwanted adverse effects including respiratory depression, constipation, immune suppression and with prolonged treatment, tolerance, dependence and abuse liability. Studies in β-arrestin 2 gene knockout (βarr2( / )) animals indicate that morphine analgesia is potentiated − − while side effects are reduced, suggesting that drugs biased away from arrestin may manifest with a reduced-side-effect profile. However, there is controversy in this area with improvement of morphine-induced constipation and reduced respiratory effects in βarr2( / ) mice. Moreover, − − studies performed with mice genetically engineered with G-protein-biased mu receptors suggested increased sensitivity of these animals to both analgesic actions and side effects of opioid drugs.
  • Summary Analgesics Dec2019

    Summary Analgesics Dec2019

    Status as of December 31, 2019 UPDATE STATUS: N = New, A = Advanced, C = Changed, S = Same (No Change), D = Discontinued Update Emerging treatments for acute and chronic pain Development Status, Route, Contact information Status Agent Description / Mechanism of Opioid Function / Target Indication / Other Comments Sponsor / Originator Status Route URL Action (Y/No) 2019 UPDATES / CONTINUING PRODUCTS FROM 2018 Small molecule, inhibition of 1% diacerein TWi Biotechnology / caspase-1, block activation of 1 (AC-203 / caspase-1 inhibitor Inherited Epidermolysis Bullosa Castle Creek Phase 2 No Topical www.twibiotech.com NLRP3 inflamasomes; reduced CCP-020) Pharmaceuticals IL-1beta and IL-18 Small molecule; topical NSAID Frontier 2 AB001 NSAID formulation (nondisclosed active Chronic low back pain Phase 2 No Topical www.frontierbiotech.com/en/products/1.html Biotechnologies ingredient) Small molecule; oral uricosuric / anti-inflammatory agent + febuxostat (xanthine oxidase Gout in patients taking urate- Uricosuric + 3 AC-201 CR inhibitor); inhibition of NLRP3 lowering therapy; Gout; TWi Biotechnology Phase 2 No Oral www.twibiotech.com/rAndD_11 xanthine oxidase inflammasome assembly, reduced Epidermolysis Bullosa Simplex (EBS) production of caspase-1 and cytokine IL-1Beta www.arraybiopharma.com/our-science/our-pipeline AK-1830 Small molecule; tropomyosin Array BioPharma / 4 TrkA Pain, inflammation Phase 1 No Oral www.asahi- A (ARRY-954) receptor kinase A (TrkA) inhibitor Asahi Kasei Pharma kasei.co.jp/asahi/en/news/2016/e160401_2.html www.neurosmedical.com/clinical-research;
  • The Main Tea Eta a El Mattitauli Mali Malta

    The Main Tea Eta a El Mattitauli Mali Malta

    THE MAIN TEA ETA USA 20180169172A1EL MATTITAULI MALI MALTA ( 19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2018 /0169172 A1 Kariman (43 ) Pub . Date : Jun . 21 , 2018 ( 54 ) COMPOUND AND METHOD FOR A61K 31/ 437 ( 2006 .01 ) REDUCING APPETITE , FATIGUE AND PAIN A61K 9 / 48 (2006 .01 ) (52 ) U . S . CI. (71 ) Applicant : Alexander Kariman , Rockville , MD CPC . .. .. .. .. A61K 36 / 74 (2013 .01 ) ; A61K 9 / 4825 (US ) (2013 . 01 ) ; A61K 31/ 437 ( 2013 . 01 ) ; A61K ( 72 ) Inventor: Alexander Kariman , Rockville , MD 31/ 4375 (2013 .01 ) (US ) ( 57 ) ABSTRACT The disclosed invention generally relates to pharmaceutical (21 ) Appl . No. : 15 /898 , 232 and nutraceutical compounds and methods for reducing appetite , muscle fatigue and spasticity , enhancing athletic ( 22 ) Filed : Feb . 16 , 2018 performance , and treating pain associated with cancer, trauma , medical procedure , and neurological diseases and Publication Classification disorders in subjects in need thereof. The disclosed inven ( 51 ) Int. Ci. tion further relates to Kratom compounds where said com A61K 36 / 74 ( 2006 .01 ) pound contains at least some pharmacologically inactive A61K 31/ 4375 ( 2006 .01 ) component. pronuPatent Applicationolan Publication manu saJun . decor21, 2018 deSheet les 1 of 5 US 2018 /0169172 A1 reta Mitragynine 7 -OM - nitragynine *** * *momoda W . 00 . Paynantheine Speciogynine **** * * * ! 1000 co Speclociliatine Corynartheidine Figure 1 Patent Application Publication Jun . 21, 2018 Sheet 2 of 5 US 2018 /0169172 A1
  • Opioid Crisis—An Emphasis on Fentanyl Analogs

    Opioid Crisis—An Emphasis on Fentanyl Analogs

    brain sciences Editorial Opioid Crisis—An Emphasis on Fentanyl Analogs Kabirullah Lutfy College of Pharmacy, Western University of Health Sciences, Pomona, CA 91766, USA; [email protected] Received: 21 July 2020; Accepted: 23 July 2020; Published: 27 July 2020 Abstract: Opioids are the mainstay for the management of moderate to severe pain. However, their acute use is associated with several side effects, ranging from nausea, itching, sedation, hypotension to respiratory depression, and death. Also, chronic use of these drugs can lead to the development of tolerance, dependence, and eventually addiction. The most serious side effect, lethality due to opioid-induced overdose, has reached the level of national emergency, i.e., the opioid crisis, which is now the forefront of medicine. In a detailed review (Novel Synthetic Opioids: The Pathologist’s Point of View), Frisoni and colleagues have discussed the side effects of novel licit and illicit fentanyl derivatives, as well as the related compounds which are more potent and faster acting than morphine and other conventional opioids (Frisoni, et al., 2018). These drugs affect the central nervous system (CNS) and can promote the development of addiction due to the quick rush they induce because of their faster entry into the brain. These drugs also arrest the cardiovascular and pulmonary systems, increasing the chance of respiratory arrest, leading to opioid-induced overdose morbidity and mortality. The respiratory arrest induced by opioids can be potentiated by other CNS depressants, such as alcohol or benzodiazepines, and therefore may occur more frequently in polydrug users. Therefore, the use of these newer fentanyl derivatives as well as other fast acting opioids should be avoided or limited to specific cases and must be kept out of the reach of children and adolescents who are more vulnerable to become addicted or overdose themselves.
  • Datasheet Inhibitors / Agonists / Screening Libraries a DRUG SCREENING EXPERT

    Datasheet Inhibitors / Agonists / Screening Libraries a DRUG SCREENING EXPERT

    Datasheet Inhibitors / Agonists / Screening Libraries A DRUG SCREENING EXPERT Product Name : Cebranopadol Catalog Number : T5167 CAS Number : 863513-91-1 Molecular Formula : C24H27FN2O Molecular Weight : 378.48 Description: Cebranopadol is an analgesic NOP and opioid receptor agonist with Kis of 0.9 nM, 0.7 nM, 2.6 nM, 18 nM for human NOP, μ-opioid (MOP), κ-opioid (KOP) and δ-opioid (DOP) receptor, respectively. Storage: 2 years -80°C in solvent; 3 years -20°C powder; DMSO 6 mg/mL Solubility Water Insoluble ( < 1 mg/ml refers to the product slightly soluble or insoluble ) NOP 13 nM (EC50, cell free) μ-opioid receptor 1.2 nM (EC50, cell free) Receptor (IC50) κ-opioid receptor 17 nM (EC50, cell free) δ-opioid receptor 110 nM (EC50, cell free) In vitro Activity Cebranopadol showed full agonistic efficacy at the human MOP and DOP receptors, almost full efficacy at the human NOP receptor, and partial efficacy at the human KOP receptor. In a functional [35S]GTPgS binding assay with membranes expressing the human 5-HT5A receptor, cebranopadol did not show agonistic or signirficant antagonistic effects at concentrations up to 10.0 μM [1]. In vivo Activity Cebranopadol exhibits highly potent and efficacious antinociceptive and antihypersensitive effects in several rat models of acute and chronic pain with ED50 values of 0.5-5.6 μg/kg after intravenous and 25.1 μg/kg after oral administration. Cebranopadol's duration of action is long (up to 7 hours after intravenous 12 μg/kg; >9 hours after oral 55 μg/kg in the rat tail-flick test) [1].
  • Cebranopadol, a Mixed Opioid Agonist, Reduces Cocaine Self- Administration Through Nociceptin Opioid and Mu Opioid Receptors

    Cebranopadol, a Mixed Opioid Agonist, Reduces Cocaine Self- Administration Through Nociceptin Opioid and Mu Opioid Receptors

    ORIGINAL RESEARCH published: 13 November 2017 doi: 10.3389/fpsyt.2017.00234 Cebranopadol, a Mixed Opioid Agonist, Reduces Cocaine Self- administration through Nociceptin Opioid and Mu Opioid Receptors Qianwei Shen1, Yulin Deng2, Roberto Ciccocioppo1* and Nazzareno Cannella1 1 School of Pharmacy, Pharmacology Unit, University of Camerino, Camerino, Italy, 2 School of Life Sciences, Beijing Institute of Technology, Beijing, China Cocaine addiction is a widespread psychiatric condition still waiting for approved efficacious medications. Previous studies suggested that simultaneous activation of nociceptin opioid (NOP) and mu opioid (MOP) receptors could be a successful strategy to treat cocaine addiction, but the paucity of molecules co-activating both receptors with comparable potency has hampered this line of research. Cebranopadol is a non-selective opioid agonist that at nanomolar concentration activates both NOP and MOP receptors Edited by: and that recently reached phase-III clinical trials for cancer pain treatment. Here, we Jeffrey Witkin, Eli Lilly, United States tested the effect of cebranopadol on cocaine self-administration (SA) in the rat. We found Reviewed by: that under a fixed-ratio-5 schedule of reinforcement, cebranopadol (25 and 50 µg/kg) Michael A. Statnick, decreased cocaine but not saccharin SA, indicating a specific inhibition of psychostim- Eli Lilly, United States ulant consumption. In addition, cebranopadol (50 µg/kg) decreased the motivation for Linda Rorick-Kehn, Eli Lilly, United States cocaine as detected by reduction of the break point measured in a progressive-ratio Jun-Xu Li, paradigm. Next, we found that cebranopadol retains its effect on cocaine consumption University at Buffalo, United States throughout a 7-day chronic treatment, suggesting a lack of tolerance development *Correspondence: toward its effect.
  • Non Commercial Use Only

    Non Commercial Use Only

    Neurology International 2016; volume 8:6322 Neuropathic pain treatment: Differently, central NP is infrequent, including pain due to spinal cord injury; pain is multiple Correspondence: Bruno Lima Pessoa, still a challenge sclerosis (MS), post-stroke pain, and etc.2 Neuropathic Pain Division of the Usually, patients with NP can present with Neurology/Neuroscience Clinical Research Osvaldo J.M. Nascimento,1 Bruno L. lancinating, shooting and/or burning pain Subunit of Antonio Pedro University Hospital, Pessoa,1 Marco Orsini,2 Pedro Ribeiro,2 along with tingling sensation. Positive sensory Universidade Federal Fluminense (UFF), RuaSiqueira Campos, 53/1204, Copacabana, Rio Eduardo Davidovich,1 Camila Pupe,1 symptoms such as spontaneous or evoked pain Pedro Moreira Filho,1 de Janeiro, RJ, 22031-071 Brazil. in response to noxious or non-noxious stimuli E-mail: [email protected] Ricardo Menezes Dornas,1 (hyperalgesia and allodynia, respectively) may Lucas Masiero,1 Juliana Bittencourt,2 also occur.3,4 Besides, a well-performed history Key words: Neurology; pain; treatment. Victor Hugo Bastos3 and physical examination are the best tools for 1Neuropathic Pain Division, the correct diagnosis. Electrophysiological Contributions: the authors contributed equally. Neurology/Neuroscience Clinical tests, imaging, and at times histological exam- ination points to the diagnosis, although NP is Conflict of interest: the authors declare no poten- Research Subunit, Antonio Pedro still diagnosed based on clinical aspects.4 tial conflict of interest. University
  • Stembook 2018.Pdf

    Stembook 2018.Pdf

    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
  • Cebranopadol, a Novel First-In-Class Analgesic Drug Candidate: First Experience with Cancer-Related Pain for up to 26 Weeks E

    Cebranopadol, a Novel First-In-Class Analgesic Drug Candidate: First Experience with Cancer-Related Pain for up to 26 Weeks E

    390 Journal of Pain and Symptom Management Vol. 58 No. 3 September 2019 Original Article Cebranopadol, a Novel First-in-Class Analgesic Drug Candidate: First Experience With Cancer-Related Pain for up to 26 Weeks E. Dietlind Koch, MD, Sofia Kapanadze, MD, Marie-Henriette Eerdekens, MD, MBA, Georg Kralidis, PhD, Jirı´Letal, PhD, Ingo Sabatschus, MD, and Sam H. Ahmedzai, MD Innovation Unit Pain, Clinical Science (E.D.K., S.K., M.-H.E.); Data SciencesdStatistics (G.K., J.L.); Global Drug Safety (I.S.), Grunenthal€ GmbH, Aachen, Germany; and Department of Oncology (S.H.A.), University of Sheffield, Sheffield, UK Abstract Context. Pain is one of the most prevalent symptoms associated with cancer. Strong opioids are commonly used in the analgesic management of the disease, but carry the risk of severe side effects. Cebranopadol is a first-in-class drug candidate, combining nociceptin/orphanin FQ peptide and opioid peptide receptor agonism. For cancer patients, frequently experiencing multimorbidities and often exposed to polypharmacy, cebranopadol is easy to handle given its once-daily dosing, the small tablet size that enables swallowing, and the option to flexibly titrate to an effective dose. Objectives. We assessed the safety and tolerability of prolonged treatment with oral cebranopadol for up to 26 weeks in patients suffering from chronic moderate-to-severe cancer-related pain. Methods. This was a non-randomized, multi-site, open-label, single-arm clinical trial with patients who had completed a double-blind trial comparing morphine prolonged release with cebranopadol. In this extension trial, patients were treated with oral cebranopadol for up to 26 weeks.
  • Phd-Comelon-2021.Pdf

    Phd-Comelon-2021.Pdf

    Opioids in postoperative pain treatment Studies on analgesic efficacy and reduction of opioid-induced side effects Thesis for the degree philosophiae doctor Marlin Comelon, cand.med. Division of Emergencies and Critical Care Department of Anesthesiology Oslo University Hospital Ullevål, Norway & Institute of Clinical Medicine Faculty of Medicine University of Oslo Norway © Marlin Comelon, 2021 Series of dissertations submitted to the Faculty of Medicine, University of Oslo ISBN 978-82-8377-824-3 All rights reserved. No part of this publication may be reproduced or transmitted, in any form or by any means, without permission. Cover: Hanne Baadsgaard Utigard. Portrait photo: Amalie Huth Hovland Print production: Reprosentralen, University of Oslo. Table of contents 1. Acknowledgements...................................................................................................... 5 2. Abbreviations and acronyms ....................................................................................... 9 3. List of papers ............................................................................................................. 11 4. Synopsis ..................................................................................................................... 13 5. Norwegian summary .................................................................................................. 15 6. Introduction ............................................................................................................... 17 6.1 Pain physiology ......................................................................................................
  • July 2017 a View Into Upcoming Specialty and Traditional Drugs TABLE of CONTENTS

    July 2017 a View Into Upcoming Specialty and Traditional Drugs TABLE of CONTENTS

    MRx Pipeline July 2017 A view into upcoming specialty and traditional drugs TABLE OF CONTENTS EDITORIAL STAFF Introduction Maryam Tabatabai, PharmD Editor in Chief Senior Director, Drug Information Pipeline Deep Dive Carole Kerzic, RPh Executive Editor Drug Information Pharmacist Keep on Your Radar Consultant Panel Becky Borgert, PharmD, BCOP Director, Clinical Oncology Product Development Lara Frick, PharmD, BCPS, BCPP Pipeline Drug List Clinical Writer Robert Greer, RPh Director, Clinical Pharmacy Programs Glossary Yuqian Liu, PharmD Manager, Specialty Clinical Programs Troy Phelps Senior Director, Analytics Richard Pope, RPh, PharmD Senior Clinical Project Manager Jim Rebello, PharmD Vice President, Formulary Business and Clinical Strategy Nothing herein is or shall be construed as a promise or representation regarding past or future events and Magellan Rx Management expressly disclaims any and all liability relating to the use of or reliance on the information contained in this presentation. The information contained in this publication is intended for educational purposes only and should not be considered clinical, financial, or legal advice. By receipt of this publication, each recipient agrees that the information contained herein will be kept confidential and that the information will not be photocopied, reproduced, or distributed to or disclosed to others at any time without the prior written consent of Magellan Rx Management. magellanrx.com 1 | 2017 Magellan Rx Management, LLC. All rights reserved. MRX1119_0717 INTRODUCTION Welcome to the MRx Pipeline. This quarterly report offers clinical insights and competitive intelligence on anticipated drugs in development. Our universal forecast addresses trends applicable across market segments. Traditional and specialty drugs, agents under the pharmacy and medical benefits, new molecular entities, pertinent new and expanded indications for existing medications, and biosimilars are profiled in the report.
  • Cebranopadol Blocks the Escalation of Cocaine Intake and Conditioned Reinstatement Of

    Cebranopadol Blocks the Escalation of Cocaine Intake and Conditioned Reinstatement Of

    bioRxiv preprint doi: https://doi.org/10.1101/140566; this version posted May 22, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Cebranopadol blocks the escalation of cocaine intake and conditioned reinstatement of cocaine seeking in rats Giordano de Guglielmo, Alessandra Matzeu, Jenni Kononoff, Julia Mattioni, Rémi Martin- Fardon, and Olivier George Department of Neuroscience, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA Corresponding author: Giordano de Guglielmo, Department of Neuroscience, The Scripps Research Institute 10550 North Torrey Pines Road, La Jolla, CA 92037, USA Tel: +1 858 784 7102, Fax: +1 858 784 7405, E-mail: [email protected] bioRxiv preprint doi: https://doi.org/10.1101/140566; this version posted May 22, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract Cebranopadol is a novel agonist of nociceptin/orphanin FQ peptide (NOP) and opioid receptors with analgesic properties that is being evaluated in clinical Phase 2 and Phase 3 trials for the treatment of chronic and acute pain. Recent evidence indicates that the combination of opioid and NOP receptor agonism may be a new treatment strategy for cocaine addiction. We sought to extend these findings by examining the effects of cebranopadol on cocaine self-administration (0.5 mg/kg/infusion) and cocaine conditioned reinstatement in rats with extended access to cocaine. Oral administration of cebranopadol (0, 25, and 50 µg/kg) reversed the escalation of cocaine self-administration in rats that were given extended (6 h) access to cocaine, whereas it did not affect the self-administration of sweetened condensed milk (SCM).